Wall Street analysts predict that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) will post $1.73 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Pieris Pharmaceuticals’ earnings. The lowest sales estimate is $1.00 million and the highest is $2.45 million. Pieris Pharmaceuticals posted sales of $790,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 119%. The company is scheduled to announce its next quarterly earnings results on Wednesday, November 8th.

On average, analysts expect that Pieris Pharmaceuticals will report full year sales of $1.73 million for the current year, with estimates ranging from $5.20 million to $8.20 million. For the next financial year, analysts expect that the business will post sales of $7.00 million per share, with estimates ranging from $5.40 million to $8.60 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Pieris Pharmaceuticals.

PIRS has been the topic of a number of recent research reports. BidaskClub lowered Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 26th. HC Wainwright set a $9.00 target price on Pieris Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 2nd. Four investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $9.00.

Pieris Pharmaceuticals (NASDAQ PIRS) opened at 5.28 on Wednesday. Pieris Pharmaceuticals has a one year low of $1.30 and a one year high of $6.58. The company has a 50-day moving average of $5.72 and a 200 day moving average of $5.72. The firm’s market cap is $233.95 million.

WARNING: “Pieris Pharmaceuticals, Inc. (PIRS) Expected to Announce Quarterly Sales of $1.73 Million” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/18/pieris-pharmaceuticals-inc-pirs-expected-to-announce-quarterly-sales-of-1-73-million.html.

In other Pieris Pharmaceuticals news, insider Allan Reine acquired 65,000 shares of the company’s stock in a transaction that occurred on Thursday, August 17th. The shares were purchased at an average price of $4.82 per share, with a total value of $313,300.00. Following the completion of the acquisition, the insider now directly owns 45,000 shares of the company’s stock, valued at approximately $216,900. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director James A. Geraghty acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 17th. The shares were acquired at an average cost of $4.82 per share, for a total transaction of $48,200.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at $48,200. The disclosure for this purchase can be found here. Insiders own 4.05% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System acquired a new position in Pieris Pharmaceuticals during the second quarter worth $308,000. The Manufacturers Life Insurance Company grew its holdings in Pieris Pharmaceuticals by 1,106.3% during the second quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 29,150 shares during the period. State Street Corp acquired a new position in Pieris Pharmaceuticals during the second quarter worth $2,377,000. Voya Investment Management LLC acquired a new position in Pieris Pharmaceuticals during the second quarter worth $100,000. Finally, Vanguard Group Inc. acquired a new position in Pieris Pharmaceuticals during the second quarter worth $526,000. 50.50% of the stock is currently owned by hedge funds and other institutional investors.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.